Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

31 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Corrigendum to "Combination therapy with interferon and JAK1-2 inhibitor is feasible. Proof of concept with rapid reduction in JAK2V617F-allele burden in Polycythemia Vera" [Leuk. Res. Rep. 3 (2) (2014) 73-75].
Bjørn ME, de Stricker K, Kjær L, Ellemann K, Hasselbalch HC. Bjørn ME, et al. Among authors: de stricker k. Leuk Res Rep. 2015 May 15;4(1):31. doi: 10.1016/j.lrr.2015.04.003. eCollection 2015. Leuk Res Rep. 2015. PMID: 26101742 Free PMC article.
Minimal residual disease and normalization of the bone marrow after long-term treatment with alpha-interferon2b in polycythemia vera. A report on molecular response patterns in seven patients in sustained complete hematological remission.
Larsen TS, Møller MB, de Stricker K, Nørgaard P, Samuelsson J, Marcher C, Andersen MT, Bjerrum OW, Hasselbalch HC. Larsen TS, et al. Among authors: de stricker k. Hematology. 2009 Dec;14(6):331-4. doi: 10.1179/102453309X12473408860587. Hematology. 2009. PMID: 19941739 Free article.
Long term molecular responses in a cohort of Danish patients with essential thrombocythemia, polycythemia vera and myelofibrosis treated with recombinant interferon alpha.
Stauffer Larsen T, Iversen KF, Hansen E, Mathiasen AB, Marcher C, Frederiksen M, Larsen H, Helleberg I, Riley CH, Bjerrum OW, Rønnov-Jessen D, Møller MB, de Stricker K, Vestergaard H, Hasselbalch HC. Stauffer Larsen T, et al. Among authors: de stricker k. Leuk Res. 2013 Sep;37(9):1041-5. doi: 10.1016/j.leukres.2013.06.012. Epub 2013 Jul 1. Leuk Res. 2013. PMID: 23827351
Minimal residual disease after long-term interferon-alpha2 treatment: a report on hematological, molecular and histomorphological response patterns in 10 patients with essential thrombocythemia and polycythemia vera.
Utke Rank C, Weis Bjerrum O, Larsen TS, Kjær L, de Stricker K, Riley CH, Hasselbalch HC. Utke Rank C, et al. Among authors: de stricker k. Leuk Lymphoma. 2016 Feb;57(2):348-354. doi: 10.3109/10428194.2015.1049171. Epub 2015 Jun 18. Leuk Lymphoma. 2016. PMID: 25956046
[New disease markers within the chronic myeloproliferative neoplasms].
Holmström MO, Ocias LF, Kallenbach K, Kjær L, Kristensen TK, Pallisgaard N, Petersen BL, Skov V, de Stricker K, Larsen TS, Hasselbalch HC. Holmström MO, et al. Among authors: de stricker k. Ugeskr Laeger. 2015 May 4;177(19):V12140653. Ugeskr Laeger. 2015. PMID: 25967091 Free article. Review. Danish.
Genomic profiling of a randomized trial of interferon-α vs hydroxyurea in MPN reveals mutation-specific responses.
Knudsen TA, Skov V, Stevenson K, Werner L, Duke W, Laurore C, Gibson CJ, Nag A, Thorner AR, Wollison B, Hansen DL, Ellervik C, El Fassi D, de Stricker K, Ocias LF, Brabrand M, Bjerrum OW, Overgaard UM, Frederiksen M, Kristensen TK, Kruse TA, Thomassen M, Mourits-Andersen T, Severinsen MT, Stentoft J, Starklint J, Neuberg DS, Kjaer L, Larsen TS, Hasselbalch HC, Lindsley RC, Mullally A. Knudsen TA, et al. Among authors: de stricker k. Blood Adv. 2022 Apr 12;6(7):2107-2119. doi: 10.1182/bloodadvances.2021004856. Blood Adv. 2022. PMID: 34507355 Free PMC article. Clinical Trial.
31 results